Our executive and administrative offices are located in downtown Toronto.

In December 2000 we opened expanded laboratory facilities, also in downtown Toronto, and we're currently completing work on a pilot manufacturing facility in the same commercial complex. We are now well positioned to conduct additional research and development on various large-molecule applications for our platform technology, and to produce our oral insulin formulation at the levels necessary for completing late-stage clinical trials. We have applied for and are awaiting regulatory approval for these new facilities.

To prepare for larger-scale manufacturing capacity, we've purchased two additional facilities, both within 25 miles of downtown Toronto. We anticipate that these facilities could be readied for production with twelve to eighteen months of lead-time when the need arises.